| Question 1: Which of the following radiopharmaceuticals would be best matched to a drug targeted to cell cycle inhibitors? |
| Reference: | Farwell MD, Clark AS, Mankoff DA. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy. JAMA Oncol. 2015 Jul;1(4):421-2. |
| Choice A: | 18F-fluorodexoyglucose (FDG) |
| Choice B: | 18F-fluorothymidine (FLT) |
| Choice C: | 18F-fluoroestradiol (FES) |
| Choice D: | 18F-fluoromisonidazole (FMISO) |
| Question 2: Which of the following is an example of an integral imaging biomarker? |
| Reference: | Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clinical trials. J Nucl Med. 2014 Apr;55(4):525-8. |
| Choice A: | Comparing the change in FDG uptake with systemic treatment to therapeutic response measured by CT. |
| Choice B: | Comparing the change in FDG uptake with systemic treatment to overall survival. |
| Choice C: | Using the location of the lesion determined by FDG PET/CT to direct locoregional therapy. |
| Choice D: | Comparing the location of the lesion determined by FDG PET/CT to the response to locoregional therapy. |
| Question 3: Which molecular imaging (MI) tool(s) can be used to improve the treatment outcome in radiation oncology? |
| Reference: | Munley MT, Kagadis GC, McGee KP, Kirov AS, Jang S, Mutic S, Jeraj R, Xing L, Bourland JD. An introduction to molecular imaging in radiation oncology: a report by the AAPM Working Group on Molecular Imaging in Radiation Oncology (WGMIR). Medical physics 2013 Oct;40(10):101501. |
| Choice A: | PET. |
| Choice B: | X-ray CT. |
| Choice C: | MRI. |
| Choice D: | Ultrasound. |
| Choice E: | Optical systems. |
| Choice F: | All the above. |
| Question 4: Which MI tool(s) can provide the information on the cell proliferation capacity of tumor? |
| Reference: | Munley MT, Kagadis GC, McGee KP, Kirov AS, Jang S, Mutic S, Jeraj R, Xing L, Bourland JD. An introduction to molecular imaging in radiation oncology: a report by the AAPM Working Group on Molecular Imaging in Radiation Oncology (WGMIR). Medical physics 2013 Oct;40(10):101501. |
| Choice A: | FGD PET |
| Choice B: | FLT PET |
| Choice C: | DCE MRI |
| Choice D: | fMRI |
| Choice E: | Spectral CT |
| Question 5: The proportion of women who undergo breast conservation surgery and have positive surgical margins is |
| Reference: | Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with wholebreast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014;21(3):704–16. |
| Choice A: | 10% |
| Choice B: | 25% |
| Choice C: | 40% |
| Choice D: | 50% |
| Question 6: Which of the following factors does not influence uptake of the fluorescent dye Indocyanine green (ICG) in breast cancers: |
| Reference: | Mondal SB, Gao S, Zhu N, et al. Optical see-through cancer vision goggles enable direct patient visualization and real-time flurescence-guided oncologic surgery. Ann Surg Oncol. 2017;24(7)1897-1903 |
| Choice A: | ICG has an active cancer-targeting mechanism |
| Choice B: | ICG passively accumulates in tumors because of distorted vasculature |
| Choice C: | ICG binds to blood proteins in the tumor environment |
| Choice D: | ICG distribution and drainage is improved with breast massage after injection |
